Egetis Therapeutics AB (LTS:0ABW)

kr 6.67 0 (0%) Market Cap: 2.55 Bil Enterprise Value: 2.54 Bil PE Ratio: 0 PB Ratio: 6.11 GF Score: 47/100

Q3 2024 Egetis Therapeutics AB (publ) Earnings Call Transcript
Nov 08, 2024

kr4.24

Earnings
Egetis Therapeutics AB Egetis Investor Day Transcript
Dec 19, 2023
Egetis Therapeutics AB (publ) To Discuss Demonstrating Treatment effects on T3 levels in MCT8-deficiency marketing approval for Emcitate® in the US Call Transcript
Jan 18, 2022

Egetis Therapeutics AB (publ) To Discuss Demonstrating Treatment effects on T3 levels in MCT8-deficiency marketing approval for Emcitate® in the US Call Transcript

Jan 18, 2022 / 02:00PM GMT

Transcript

Nicklas Westerholm

Egetis Therapeutics AB - CEO

Thank you very much, operator. Good afternoon and good morning to everyone on the call. And a warm welcome to this update by Egetis Therapeutics with focus on Emcitate and this morning's announcement. Please note that the slides used during today's webcast could also be found at the company's website.

Next slide, please. And next slide. So we're now on slide number 3.

For those I haven't had the privilege to meet, I am Nicklas Westerholm, the CEO of Egetis Therapeutics. With me today, I also have Kristina SjÃ¶blom Nygren, Chief Medical Officer; Yilmaz Mahshid, Chief Financial Officer; Christian Sonesson, VP, Product Strategy and Development; Henrik Krook, VP Commercial Operations; and Peder Walberg, Operating Director of the Board.

Next slide please. The agenda will be as follows. We will start with providing an overview of Egetis Therapeutics and our lead candidate, Emcitate. We will then of course focus on the positive announcement this morning where we have concluded that demonstrating a treatment effect on T3 levels in MCT8

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.